Reported Tuberculosis in the United States, 2017
Table 51. Tuberculosis Cases and Percentages, by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20151
Reporting Area | Total Cases | Therapy ≤1 year indicated2,3,4 | Therapy >1 year indicated3,5 | |||
---|---|---|---|---|---|---|
No. | COT ≤1 year(%) | COT(%) | No. | COT(%) | ||
United States | 9,547 | 7,860 | (89.5) | (95.8) | 519 | (90.2) |
Alabama | 119 | 98 | (85.7) | (95.9) | 6 | (100.0) |
Alaska | 68 | 59 | (93.2) | (100.0) | 5 | (100.0) |
Arizona | 198 | 151 | (92.1) | (98.0) | 9 | (88.9) |
Arkansas | 90 | 79 | (84.8) | (96.2) | 4 | (100.0) |
California | 2,131 | 1,764 | (88.2) | (95.4) | 105 | (87.6) |
Colorado | 73 | 61 | (95.1) | (96.7) | 6 | (100.0) |
Connecticut | 70 | 56 | (94.6) | (100.0) | 6 | (100.0) |
Delaware | 22 | 18 | (88.9) | (100.0) | 2 | (100.0) |
District of Columbia | 33 | 24 | (87.5) | (95.8) | 2 | (100.0) |
Florida | 602 | 496 | (95.6) | (98.4) | 34 | (88.2) |
Georgia | 320 | 270 | (90.4) | (97.8) | 17 | (100.0) |
Hawaii | 127 | 113 | (95.6) | (99.1) | 6 | (100.0) |
Idaho | 11 | 9 | (100.0) | (100.0) | 1 | (100.0) |
Illinois | 343 | 289 | (94.5) | (98.6) | 15 | (100.0) |
Indiana | 116 | 101 | (94.1) | (96.0) | 5 | (100.0) |
Iowa | 38 | 34 | (85.3) | (91.2) | 1 | (100.0) |
Kansas | 36 | 32 | (93.8) | (96.9) | 3 | (66.7) |
Kentucky | 67 | 53 | (94.3) | (100.0) | 7 | (100.0) |
Louisiana | 119 | 107 | (65.4) | (72.9) | 4 | (75.0) |
Maine | 18 | 15 | (100.0) | (100.0) | 1 | (100.0) |
Maryland | 176 | 141 | (90.8) | (98.6) | 14 | (92.9) |
Massachusetts | 192 | 151 | (88.7) | (97.4) | 15 | (93.3) |
Michigan | 131 | 112 | (95.5) | (99.1) | 4 | (100.0) |
Minnesota | 150 | 125 | (95.2) | (97.6) | 15 | (93.3) |
Mississippi | 73 | 55 | (89.1) | (96.4) | 3 | (100.0) |
Missouri | 92 | 77 | (81.8) | (88.3) | 5 | (80.0) |
Montana | 9 | 7 | (100.0) | (100.0) | 1 | (100.0) |
Nebraska | 33 | 27 | (37.0) | (37.0) | 3 | (0.0) |
Nevada | 85 | 71 | (94.4) | (98.6) | 3 | (100.0) |
New Hampshire | 13 | 7 | (100.0) | (100.0) | 3 | (100.0) |
New Jersey | 326 | 254 | (90.9) | (97.2) | 20 | (85.0) |
New Mexico | 47 | 29 | (93.1) | (96.6) | 2 | (100.0) |
New York State6 | 188 | 149 | (94.0) | (97.3) | 12 | (83.3) |
New York City | 575 | 489 | (94.1) | (98.0) | 35 | (97.1) |
North Carolina | 199 | 162 | (92.6) | (99.4) | 12 | (100.0) |
North Dakota | 9 | 7 | (85.7) | (85.7) | 0 | … |
Ohio | 143 | 116 | (83.6) | (93.1) | 6 | (100.0) |
Oklahoma | 67 | 59 | (88.1) | (96.6) | 0 | … |
Oregon | 76 | 64 | (89.1) | (95.3) | 5 | (100.0) |
Pennsylvania | 200 | 165 | (80.6) | (93.3) | 5 | (100.0) |
Rhode Island | 30 | 23 | (100.0) | (100.0) | 2 | (100.0) |
South Carolina | 104 | 86 | (91.9) | (94.2) | 4 | (100.0) |
South Dakota | 17 | 14 | (50.0) | (78.6) | 0 | … |
Tennessee | 131 | 106 | (95.3) | (96.2) | 10 | (90.0) |
Texas | 1,334 | 1,089 | (87.5) | (94.5) | 70 | (82.9) |
Utah | 37 | 31 | (93.5) | (96.8) | 5 | (100.0) |
Vermont | 7 | 7 | (100.0) | (100.0) | 0 | … |
Virginia | 212 | 180 | (92.2) | (97.2) | 10 | (100.0) |
Washington | 207 | 162 | (74.1) | (90.1) | 13 | (76.9) |
West Virginia | 10 | 6 | (83.3) | (100.0) | 1 | (0.0) |
Wisconsin | 69 | 58 | (86.2) | (100.0) | 2 | (50.0) |
Wyoming | 4 | 2 | (100.0) | (100.0) | 0 | … |
American Samoa7 | 4 | 4 | (0.0) | (0.0) | 0 | … |
Fed. States of Micronesia7 | 103 | 93 | (90.3) | (91.4) | 2 | (50.0) |
Guam7 | 76 | 66 | (60.6) | (62.1) | 3 | (66.7) |
Marshall Islands7 | 136 | 118 | (87.3) | (91.5) | 2 | (100.0) |
N. Mariana Islands7 | 27 | 25 | (80.0) | (88.0) | 1 | (100.0) |
Puerto Rico7 | 52 | 38 | (73.7) | (86.8) | 2 | (100.0) |
Republic of Palau7 | 14 | 11 | (90.9) | (90.9) | 2 | (100.0) |
U.S. Virgin Islands7 | 0 | … | … | … | … | … |
1 Most recent year for which data are available.
2 Initial isolate susceptible to rifampin (n = 5,915) or susceptibility unknown (n = 74); culture negative (n = 1,566); culture status unknown (n = 305).
3 Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia).
4 Therapy ≤1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who moved out of the country within one year of initiating treatment.
5 Initial isolate rifampin resistant, or patient with meningeal disease or bone and joint disease, or disease of the central nervous system, or pediatric patient (age <15) with miliary disease or positive blood culture or a positive nucleic acid amplification test on a blood specimen, and those who did not move out of the country or die during treatment.
6 Excludes New York City.
7 Not included in U.S. totals.
Note: Ellipses (…) indicate that the percentage cannot be calculated, and the denominator is 0.
See Technical Notes for description of completion of therapy calculation.